These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30238965)

  • 1. Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.
    Chu X; Galetin A; Zamek-Gliszczynski MJ; Zhang L; Tweedie DJ;
    Clin Pharmacol Ther; 2018 Nov; 104(5):788-792. PubMed ID: 30238965
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
    Akamine Y; Yasui-Furukori N; Uno T
    Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate.
    Shi JG; Zhang Y; Yeleswaram S
    Nat Rev Drug Discov; 2011 Jan; 10(1):75; author reply 75. PubMed ID: 21193869
    [No Abstract]   [Full Text] [Related]  

  • 4. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
    Zhang H; Yao M; Morrison RA; Chong S
    Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
    Zhao Y; Hu ZY
    Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells.
    Zhang S; Morris ME
    Pharm Res; 2003 Aug; 20(8):1184-91. PubMed ID: 12948016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digestion of surfactants does not affect their ability to inhibit P-gp-mediated transport in vitro.
    Rasmussen AJ; Pedersen M; Griffin BT; Holm R; Nielsen CU
    Int J Pharm; 2024 May; 656():124120. PubMed ID: 38621613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loxapine P-glycoprotein interactions in vitro.
    Reed A; Huie K; Perloff ES; Cassella JV; Takahashi LH
    Drug Metab Lett; 2012 Mar; 6(1):26-32. PubMed ID: 22300294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition.
    Yamazaki S; Evers R; De Zwart L
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):55-67. PubMed ID: 34668334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux.
    Oga EF; Sekine S; Horie T
    Drug Metab Pharmacokinet; 2013; 28(4):314-20. PubMed ID: 23291634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation.
    Cui C; Qu Y; Sia JEV; Zhu Z; Wang Y; Ling J; Li H; Jiang Y; Pan J; Liu D
    Clin Pharmacokinet; 2022 Dec; 61(12):1789-1800. PubMed ID: 36378486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport.
    Nielsen RB; Kahnt A; Dillen L; Wuyts K; Snoeys J; Nielsen UG; Holm R; Nielsen CU
    Int J Pharm; 2019 Nov; 571():118696. PubMed ID: 31525443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
    Hughes J; Crowe A
    J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
    Udomnilobol U; Jianmongkol S; Prueksaritanont T
    Drug Metab Dispos; 2023 Sep; 51(9):1216-1226. PubMed ID: 37230768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R; Surry DD; Smith VN; Gray AJ
    Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
    Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
    Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan-induced gastrointestinal damage impairs the absorption of dabigatran etexilate.
    Hattori T; Imaoka A; Akiyoshi T; Ohtani H
    Biopharm Drug Dispos; 2019 Nov; 40(9):315-324. PubMed ID: 31642538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Acanthopanax senticosus HARMS extract on drug transport in human intestinal cell line Caco-2.
    Takahashi T; Kaku T; Sato T; Watanabe K; Sato J
    J Nat Med; 2010 Jan; 64(1):55-62. PubMed ID: 20091240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
    Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.